Bamco Inc. NY Has $18.41 Million Holdings in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Bamco Inc. NY lifted its stake in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 43.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,123,651 shares of the company’s stock after buying an additional 640,000 shares during the period. Bamco Inc. NY owned about 0.84% of Maravai LifeSciences worth $18,412,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. 12 West Capital Management LP increased its stake in shares of Maravai LifeSciences by 13.8% in the first quarter. 12 West Capital Management LP now owns 13,202,988 shares of the company’s stock valued at $114,470,000 after buying an additional 1,600,000 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Maravai LifeSciences by 0.3% in the first quarter. Vanguard Group Inc. now owns 10,038,126 shares of the company’s stock worth $87,031,000 after acquiring an additional 34,232 shares during the last quarter. Mackenzie Financial Corp lifted its position in shares of Maravai LifeSciences by 4.8% during the fourth quarter. Mackenzie Financial Corp now owns 5,169,176 shares of the company’s stock worth $33,858,000 after purchasing an additional 238,335 shares in the last quarter. Braidwell LP grew its stake in shares of Maravai LifeSciences by 26.8% during the fourth quarter. Braidwell LP now owns 5,040,635 shares of the company’s stock valued at $33,016,000 after purchasing an additional 1,065,778 shares during the last quarter. Finally, Point72 Europe London LLP acquired a new stake in shares of Maravai LifeSciences in the fourth quarter valued at approximately $17,059,000. Institutional investors own 50.25% of the company’s stock.

Analyst Upgrades and Downgrades

MRVI has been the subject of a number of recent analyst reports. Craig Hallum assumed coverage on Maravai LifeSciences in a research note on Wednesday, April 10th. They issued a “buy” rating and a $15.00 price target for the company. Robert W. Baird increased their price target on Maravai LifeSciences from $8.00 to $10.00 and gave the company an “outperform” rating in a research report on Thursday, May 9th. Finally, The Goldman Sachs Group decreased their price objective on shares of Maravai LifeSciences from $8.00 to $7.00 and set a “neutral” rating for the company in a research report on Tuesday, July 9th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $11.44.

Insider Activity

In related news, Director Gtcr Investment Xi Llc sold 9,940,974 shares of the company’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $9.81, for a total transaction of $97,520,954.94. Following the completion of the transaction, the director now directly owns 20,150,005 shares in the company, valued at approximately $197,671,549.05. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.63% of the stock is currently owned by corporate insiders.

Maravai LifeSciences Price Performance

Shares of NASDAQ MRVI traded up $0.65 during trading hours on Friday, hitting $9.16. 1,261,621 shares of the stock were exchanged, compared to its average volume of 2,373,665. Maravai LifeSciences Holdings, Inc. has a 1-year low of $4.52 and a 1-year high of $12.10. The company has a market cap of $2.31 billion, a PE ratio of -9.25 and a beta of 0.02. The company has a debt-to-equity ratio of 0.71, a quick ratio of 10.47 and a current ratio of 11.32. The company’s fifty day simple moving average is $8.38 and its two-hundred day simple moving average is $7.82.

Maravai LifeSciences (NASDAQ:MRVI) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.05). Maravai LifeSciences had a negative net margin of 47.81% and a negative return on equity of 4.28%. The business had revenue of $64.18 million during the quarter, compared to the consensus estimate of $60.84 million. On average, sell-side analysts predict that Maravai LifeSciences Holdings, Inc. will post -0.15 EPS for the current year.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.